Australia-based biomanufacturing innovator Cauldron Ferm has successfully closed a $13.25 million Series A2 funding round, bringing its total investment raised to $26 million. The financing round was led by Main Sequence Ventures, with participation from Horizons Ventures, SOSV, and NGS Super, one of Australia’s largest pension funds.
The new capital will accelerate Cauldron’s commercial expansion, including the scaling of its cutting-edge hyper-fermentation technology and the development of demonstration facilities in Orange, New South Wales. The company has also secured government grants in both Australia and the United States to further support technology deployment and research initiatives.
Brandspur Business News reports that Cauldron Ferm’s continuous fermentation platform is designed to maintain bio-engineered microbes in a highly productive, stable state over extended periods, boosting output while reducing production costs. The technology targets a broad spectrum of applications, from food ingredients and nutraceuticals to industrial chemicals, positioning bio-based production as a competitive alternative to conventional manufacturing.
The firm has demonstrated its platform at a 10,000-litre industrial scale, showcasing its ability to operate continuous fermentation for synthetic biology strains. Ongoing projects include retrofitting existing facilities to accommodate the system, enabling widespread adoption of scalable bio-manufacturing solutions.
Co-founder and CEO Michele Stansfield explained: “For biomanufacturing to compete with traditional industrial sectors, it must deliver cost efficiency, scalability, and quality. Our hyper-fermentation process is the key to achieving this.”
Investment partners highlighted the strategic potential of the technology. Ben Squires, Chief Investment Officer at NGS Super, noted that backing Cauldron aligns with the firm’s focus on enhancing industrial productivity and economic efficiency at scale.
Industry experts predict that as demand for resilient and flexible supply chains rises, innovations like Cauldron Ferm’s platform will play a critical role in shaping the future of industrial bio-manufacturing.
